Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

876
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
876

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute degron-mediated RUNX1 loss reprograms enhancer activity to epigenetically drive epithelial destabilization and initiate cancer hallmarks.

bioRxiv : the preprint server for biology·2026
Same author

Unraveling the complexity of the histone code: implications for gene regulation and disease.

Genome biology·2026
Same author

IKAROS Gene Regulatory Network Reveal ERG as a Vulnerability in B-cell Acute Lymphoblastic Leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Successful Resolution of Compartment Syndrome in a Pediatric Patient With B-cell Acute Lymphoblastic Leukemia.

Journal of pediatric hematology/oncology·2025
Same author

An Epigenetic Perspective of Gene Expression: The Regulatory Tools.

Critical reviews in eukaryotic gene expression·2025
Same author

Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity.

Cancer research·2025
Same journal

Overlapping gut microbiome signatures in aging and disease are characterized by enrichment of medication-associated oral microbes in the gut.

FEBS letters·2026
Same journal

Csk binding to integrin β3 is regulated by tyrosine and threonine phosphorylation of β3.

FEBS letters·2026
Same journal

Mixed-class J-domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assembly.

FEBS letters·2026
Same journal

Design and analysis strategies for robust microbiome ageing research.

FEBS letters·2026
Same journal

Reconstructing enzyme evolution by protein engineering.

FEBS letters·2026
Same journal

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates.

FEBS letters·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.4K

PICALM::MLLT10 translocated leukemia.

John M Cullen1, Antonia C Nakatsugawa1, Natalie Barton1

  • 1Department of Pediatrics, University of Vermont Larner College of Medicine, Burlington, USA.

FEBS Letters
|January 14, 2026
PubMed
Summary
This summary is machine-generated.

The PICALM::MLLT10 chromosomal translocation drives acute leukemia through epigenetic changes. Targeting this leukemia with venetoclax shows promising results, offering new hope for patients.

Keywords:
PICALM::MLLT10CALM‐AF10epigenetic controlleukemialeukemia translocation

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

627

Related Experiment Videos

Last Updated: Jan 15, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.4K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

627

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The t(10;11)(p13;q14-21) translocation creates the CALM-AF10 fusion oncoprotein, a key driver in acute myeloid and T-lymphoblastic leukemia.
  • This leukemia subtype is characterized by epigenetic dysregulation, including global hypomethylation leading to genomic instability and focal H3K79 hypermethylation driving proliferation.

Purpose of the Study:

  • To provide an updated overview of the pathophysiology, clinical presentation, prognosis, and treatment of PICALM::MLLT10 acute leukemia.
  • To highlight potential therapeutic targets based on a deeper biological understanding of the disease.

Main Methods:

  • Review of existing literature and patient data.
  • Analysis of the molecular mechanisms driving PICALM::MLLT10 leukemia, including epigenetic alterations and protein interactions.
  • Evaluation of recent therapeutic interventions, such as venetoclax treatment.

Main Results:

  • PICALM::MLLT10 leukemia exhibits distinct epigenetic features influencing genomic stability and gene expression.
  • The translocation is associated with a poor prognosis and chemotherapy resistance.
  • Recent studies show promising efficacy of venetoclax, a BCL2 inhibitor, in treating PICALM::MLLT10 acute leukemia.

Conclusions:

  • PICALM::MLLT10 acute leukemia is an epigenetically driven malignancy with specific clinical and prognostic implications.
  • Emerging therapeutic strategies, including targeted therapies like venetoclax, offer new treatment avenues for this challenging leukemia subtype.